Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population
The Oncologist · 08.07.2026 · 31 (8)
DOI: 10.1093/oncolo/oyag255 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 03.07.2026. Verfasst von Ninna Aggerholm-Pedersen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sarcoma Centre of Aarhus University Hospital, Aarhus N, 8200, Denmark. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Nerve Sheath Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish NF Patient Association NF Danmark, Max Wørzner and Inger Wørzner's memorial trust and the Dagmar Marshall Foundation, Max Wørzner and Inger Wørzner’s memorial trust and the Dagmar Marshall Foundation.
Abstract (Originalsprache)
Purpose
While neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (nfMPNST) is often considered to have a particularly poor prognosis compared to sporadic malignant peripheral nerve sheath tumor (sMPNST), this assumption remains insufficiently substantiated. This study aimed to compare clinical characteristics, treatment outcome, and survival between nfMPNST and sMPNST in a nationwide Danish cohort. Patient and method We conducted a retrospective cohort study of patients with malignant peripheral nerve sheath tumor (MPNST) in Denmark from 2000 to 2020. NF1-associated cases were identified through a national NF1 registry, while sporadic cases of MPNST were extracted from the Danish Sarcoma Database. Clinical, pathological, and treatment data were supplemented by chart review and national pathology records. Survival outcomes were analyzed using Kaplan–Meier estimates and Cox proportional hazards models.
Results
A total of 146 patients were included, of which 42 had nfMPNST and 104 sMPNST. Patients with nfMPNST were significantly younger at diagnosis (median 37 [min-max: 12-73] vs 58 [min-max: 5-93] years, P < .001) and had larger tumors (>5 cm in 88% vs 50%, P < .001). Wide margin resection was achieved less often in nfMPNST (35% vs 66%, P = .003), and adjuvant radiotherapy was more commonly administered (61% vs 36%). Five-year overall survival for localized disease was significantly lower in nfMPNST (44% vs 63%, P = .03), with higher recurrence rates (69% vs 49%, P = .049) and shorter time to recurrence (median 2.2 vs 3.4 years). Among 27 sMPNST tumors analyzed by next-generation sequencing, 5 (19%) harbored pathogenic NF1 variants. Conclusion nfMPNST presents at a younger age with more aggressive features and worse outcomes compared to sporadic cases. These findings support the need for tailored surveillance and treatment strategies in NF1 patients and highlight the potential role of NF1 alterations in sMPNST pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Sarcoma Centre of Aarhus University Hospital, Aarhus N, 8200, Denmark.
- Centre for Rare Diseases, Pediatrics and Adolescent Medicine, Aarhus N, 8200, Danmark.
- Department of Oncology, Copenhagen University Hospital, Herlev, 2730, Denmark.
- Department of Pathology, Sarcoma Center of Aarhus University Hospital, Aarhus N, 8200, Denmark.
- Department of Orthopedic Surgery, Sarcoma Center of Aarhus University Hospital, Aarhus N, 8200, Denmark.
- Department of Pediatric and Adolescent Medicine, Centre for Rare Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, 2100, Denmark.
ORCID-Profile: Ninna Aggerholm-Pedersen
Förderung
- Danish NF Patient Association NF Danmark
- Max Wørzner and Inger Wørzner's memorial trust and the Dagmar Marshall Foundation
- Max Wørzner and Inger Wørzner’s memorial trust and the Dagmar Marshall Foundation
Zitieren
APA
Aggerholm-Pedersen, N., Handrup, M. M., Thomassen, S. B., Engelmann, B., Kongstad, K. M., Jakobsen, M. V., Baad-Hansen, T., Farholt, S., Thomas, D., & Ejerskov, C. (2026). Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag255
Vancouver
Aggerholm-Pedersen N, Handrup MM, Thomassen SB, Engelmann B, Kongstad KM, Jakobsen MV, et al. Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag255
BibTeX
@article{AggerholmPedersen2026,
author = {Aggerholm-Pedersen, Ninna and Handrup, Mette Møller and Thomassen, Stine Bogestofte and Engelmann, Bodil and Kongstad, Katja Maretty and Jakobsen, Maria Vad and Baad-Hansen, Thomas and Farholt, Stense and Thomas, David and Ejerskov, Cecilie},
title = {Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {8},
doi = {10.1093/oncolo/oyag255}
}
EUVIMED